Home » Topics » Regulatory » EMA

EMA
RSS

Orbus Therapeutics' brain cancer drug receives EMA orphan medicinal product status

June 20, 2016

GM-604 receives E.U. orphan drug designation for ALS

June 10, 2016

Protalix BioTherapeutics initiates global phase III study of PRX-102 in Fabry disease

June 7, 2016

Kite Pharma granted access to European PRIME initiative for KTE-C19 in DLBCL

June 2, 2016

Can-Fite reaches agreement with EMA for piclidenoson phase III trial

June 2, 2016

CCX-168 receives EMA PRIME designation for AAV

June 2, 2016

QR-110 from ProQR Therapeutics receives U.S. and E.U. orphan drug designations

June 2, 2016

EMA committee supports expanding approval of Tysabri

June 1, 2016

BioMarin withdraws Kyndrisa MAA, discontinues development of follow-on products

June 1, 2016

Simponi receives positive opinion in Europe for treatment of pJIA

May 31, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...